Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer

Nishida, Naohiro; Sakai, Daisuke; Satoh, Taroh

International Journal of Clinical Oncology, 2024, 29(9), 1237-1243

Number of Access:423（2025-08-14 15:05 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/96463

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
IntJClinOncol_s10147_024_02500_8 pdf None 0.99 MB 149 2024.06.27  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer
Creator
NRID
1000050588118 1000050588118
researchmap permalink
naohiro_nishida naohiro_nishida
CreatorName
Nishida, Naohiro
NRID
1000010621071 1000010621071
CreatorName
Sakai, Daisuke
NRID
1000040368303 1000040368303
ORCID
0000-0002-4615-2638 0000-0002-4615-2638
researchmap permalink
TarohSatoh TarohSatoh
Scopus Author ID
12040860900 12040860900
CreatorName
Satoh, Taroh
Subject
Advanced gastric cancer
Anti-VEGF treatment
Immune checkpoint inhibitor (ICI)
Later-line treatment
Tyrosine kinase inhibitors (TKIs)
Description
The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02500-8.
Abstract
After immune checkpoint inhibitor (ICI) comes into third-line treatment of advanced gastric cancer, the therapeutic strategy has been dramatically changed. Recent first-line regimen, which consists of ICI and chemotherapeutic agents, prolonged progression-free survival, and subsequent treatment options enabled continuous treatment beyond second-line therapy. Moreover, the advent of vascular endothelial growth factor (VEGF)-targeted agents including angiogenesis inhibitors and TKIs provides an opportunity of considering the interaction between ICI and anti-VEGF agents, and facilitating novel treatment proposal. Although clinical benefit of prolonged VEGF blockade after disease progression has not been confirmed in gastric cancer, combination therapy of cytotoxic agents and anti-VEGF agent, such as irinotecan plus ramucirumab demonstrated favorable objective response rate and progression-free survival in third- or later-line setting. In this review, we discuss recent progress and future directions of later-line treatments of HER2-negative advancer gastric cancer.
Publisher
Springer
Source Title
International Journal of Clinical Oncology
Volume (Issue)
29(9)
Page
1237-1243
Date of Issued
2024-05-11
Language
English
Handle URL
https://hdl.handle.net/11094/96463
PISSN
13419625
eISSN
14377772
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1007/s10147-024-02500-8
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article